Sovran Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Sovran Advisors's VRTX Position: Q2 2026 in Review
Sovran Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 6.3% in Q2 2026, buying an estimated $38.6K and bringing the position to 1,479 shares worth $725K. The position accounts for 0.05% of the portfolio, ranked #298.
Sovran Advisors first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.68M in Q1 2025. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Sovran Advisors held 1,479 shares of Vertex Pharmaceuticals worth $725K as of Q2 2026.
- Sovran Advisors bought 87 Vertex Pharmaceuticals shares in Q2 2026, an estimated $38.6K.
- Vertex Pharmaceuticals made up 0.05% of Sovran Advisors's portfolio in Q2 2026, its #298 holding.
- Sovran Advisors first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
- Sovran Advisors's Vertex Pharmaceuticals position peaked at $2.68M in Q1 2025.
- 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Sovran Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.